

For Immediate Release

December 16, 2008

Contact:

Mary Kuramoto

513-579-9911 x 2523

www.m.kuramoto@medpace.com**Medpace Strengthens Clinical Development Services with Medpace Bioanalytical Laboratories**

Cincinnati, OH (December 16, 2008) - Medpace, Inc., a leading full-service global clinical research organization, today announced the opening of the new Medpace Bioanalytical Laboratories, strengthening its suite of clinical development services for Pharmaceutical and Biotechnology companies. The new Laboratory complements services provided by other Medpace research facilities, such as Medpace Clinical Pharmacology and Medpace Reference Laboratories. The addition of Bioanalytical capabilities will allow Medpace to provide full service for Phase I-IV Studies on a global footprint. With clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and assist with regulatory requirements worldwide.

Medpace Bioanalytical Laboratories is led by industry pioneer, Dr. Yong-Xi Li, formerly of Eurofins Scientific, N.J. Dr. Li will direct operations and activities of the Laboratory in the areas of method transfer, development, validation, and analysis of preclinical and clinical biological samples. Prior to his work at Eurofins Scientific, Dr. Li was Vice President of Ricerca LLC and the Vice President, XenoBiotics Laboratories, Inc., where he led and expanded the bioanalytical laboratories and activities. Dr. Li is an industry expert with vast knowledge in the development of over 300 methods to analyze drug compounds. Dr. Li will lead a working team of advanced degreed scientists performing qualitative and quantitative analysis on both animal and human biologic samples.

"We are pleased to provide another service to our sponsors in the area of Bioanalytics," said Dr. August Troendle, President and CEO of Medpace. "The knowledge of Dr. Li's team, combined with the most current technology available, will help our customers by providing higher quality analysis than the industry has previously experienced, expediting compound development and the likelihood of sponsor success."

Medpace Bioanalytical Laboratories is one of the first Laboratories in North America to use the latest instrumentation in mass spectrometry: the AB SCIEX QTRAP® 5500 System from Applied Biosystems, part of Life Technologies. The system, which was developed through a joint venture between Applied Biosystems and MDS Analytical Technologies, integrates triple quadrupole capabilities with a new innovation in ion trap technology called Linear Accelerator™ Trap for quantitative and qualitative analysis. According to Dr. Li, "This equipment is the only system on the market that seamlessly integrates industry-leading sensitivity and high performance for both quantitative and qualitative analysis, enabling a greater number of compounds, proteins, and contaminants to be analyzed."

Other Medpace Bioanalytical instrumentation includes Applied Biosystems/MDS Analytical Technologies triple quadrupole systems, including the API 4000 LC-MS/MS Systems. For liquid chromatography, the Laboratory uses HPLC UFLC/LC-20 Systems from Shimadzu.

Medpace Bioanalytical Laboratories, with the help of technologies from Applied Biosystems, provide researchers with complete workflow solutions that are unmatched in terms of functionality, speed and performance. This innovative equipment is made to: increase sensitivity and speed in qualitative analysis; drive the highest quantitative accuracy to the lowest levels of detection for mass spectrometry systems; and significantly accelerate the speed of analysis when compared to other instruments.

Dr. Li's expertise combined with new state-of-the-art mass spectrometry equipment will provide Medpace sponsors with a higher level of quality within the analysis process, to expedite the clinical development process for drug compounds.

###

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology. Visit the Medpace website at www.medpace.com